High Lp(a) Awareness, Low Testing: A Hidden Heart Risk in India
Despite significant awareness among clinicians about Lipoprotein(a) (Lp[a]) as a crucial genetic risk factor for cardiovascular disease, testing rates remain alarmingly low. This poses a particular concern for India, where elevated Lp(a) is highly prevalent and contributes to premature heart conditions. Experts urge for increased screening to improve risk stratification and manage modifiable factors.
Key Highlights
- Lp(a) is a genetic, independent risk factor for heart disease and stroke.
- Clinicians show high awareness of Lp(a)'s role in cardiovascular risk.
- Lp(a) testing rates are critically low, less than 1% in some populations.
- Lack of approved Lp(a)-specific therapies is a major barrier to testing.
- Elevated Lp(a) is found in 25% of Indians, contributing to earlier CAD onset.
- Current management focuses on aggressive control of other modifiable risk factors.
Lipoprotein(a), commonly known as Lp(a), has been definitively identified as an independent, genetically determined, and causal risk factor for atherosclerotic cardiovascular disease (ASCVD), including heart attack, stroke, and calcific aortic stenosis. Unlike other lipid markers, Lp(a) levels are largely stable throughout an individual's adult life and are predominantly determined by genetics, with minimal influence from lifestyle factors such as diet or exercise. This unique characteristic makes a single Lp(a) measurement a powerful tool for lifelong cardiovascular risk assessment.
The article under verification, from AJMC, highlights a critical paradox: while there is high awareness among clinicians regarding Lp(a)'s significance as a cardiovascular risk factor, actual testing rates remain strikingly low. A survey cited in the AJMC article indicated that 81% of US clinicians had a high level of awareness of Lp(a) as a significant risk factor, and 77% agreed it was a helpful risk-stratification tool. However, this awareness does not translate into widespread testing. A 2023 study of real-world data from the US revealed that less than 1% of the population had been tested for Lp(a). Another large study involving 71 million individuals found that only 0.1% had undergone Lp(a) testing, even though among those tested, 21.4% had elevated levels.
Several factors contribute to these low testing rates. A primary reason cited is the uncertainty among physicians on how to manage patients with elevated Lp(a) levels, largely due to a current lack of approved Lp(a)-targeting therapies. Other identified barriers include a general lack of awareness among the broader public, unclear or inconsistent testing guidelines, the absence of widespread testing programs, variability in clinical assays, and issues with insurance coverage. Despite these challenges, major medical bodies like the European Atherosclerosis Society (EAS), National Lipid Association (NLA), and Canadian Cardiovascular Society (CCS) now recommend measuring Lp(a) at least once in all adults as part of initial lipid screening. The American Heart Association (AHA) and American College of Cardiology (ACC) also propose testing for individuals with a personal or family history of ASCVD or familial hypercholesterolemia.
The relevance of this information for an Indian audience is particularly significant. Studies show that approximately one in five people worldwide have elevated Lp(a) levels (defined as >50 mg/dL or >125 nmol/L), but this prevalence is notably higher in Indians, estimated at 25%. South Asian individuals, including those in India, experience a disproportionate burden of cardiovascular disease, often with earlier onset and a more aggressive course, and elevated Lp(a) levels are considered a significant contributing factor that is not fully explained by traditional risk factors. In fact, South Asians account for approximately 33% of the global burden of elevated Lp(a). Cardiologists in India are increasingly advocating for early Lp(a) testing, especially for those with a family history of premature heart disease. Recent Indian studies have also correlated elevated Lp(a) with severe angiographic disease in patients with coronary artery disease. The Lipid Association of India (LAI) has recognized the unique characteristics of dyslipidemia in Indians, including the high prevalence of elevated Lp(a), necessitating tailored lipid management strategies.
Given that Lp(a) levels are genetically determined and stable, a one-time measurement can provide invaluable information for lifetime risk assessment. While specific Lp(a)-lowering medications are still undergoing clinical trials (e.g., PCSK9 inhibitors and antisense oligonucleotides like Pelacarsen show promise in reducing Lp(a) levels), current management strategies for individuals with elevated Lp(a) focus on aggressive control of all other modifiable cardiovascular risk factors. This includes intensive lifestyle modifications, such as adopting a heart-healthy diet, regular exercise, maintaining a healthy weight, cessation of tobacco use, and diligent management of conditions like high LDL cholesterol, hypertension, and diabetes. The identification of elevated Lp(a) can lead to more personalized and aggressive preventive therapies, even in patients with otherwise controlled LDL-C levels. Tools like electronic health record reminders have shown potential in boosting testing rates. Increased awareness among both clinicians and the public, coupled with improved accessibility to testing and clearer management guidelines, is crucial to address this significant, yet often overlooked, cardiovascular risk factor, particularly in populations like India with a high genetic predisposition.
Frequently Asked Questions
What is Lipoprotein(a) and why is it a risk factor for heart disease?
Lipoprotein(a), or Lp(a), is a type of lipoprotein that is primarily determined by genetics. Elevated levels of Lp(a) are an independent and causal risk factor for atherosclerotic cardiovascular disease (ASCVD), including heart attacks, strokes, and aortic stenosis, due to its pro-inflammatory, pro-thrombotic, and pro-atherogenic properties.
Why are Lp(a) testing rates low despite its known risks?
Testing rates for Lp(a) are low because many physicians are uncertain about how to manage patients with elevated levels, largely due to a current lack of approved Lp(a)-specific therapies. Other factors include insufficient public and some clinician awareness, inconsistent testing guidelines, and lack of dedicated screening programs.
How common is high Lp(a) in India, and what are its implications?
Elevated Lp(a) levels (above 50 mg/dL or 125 nmol/L) are found in approximately 25% of the Indian population, which is higher than the global average of about 20%. This high prevalence contributes to the earlier onset and more aggressive course of coronary artery disease seen in South Asian individuals, making it a critical, often overlooked, genetic risk factor for the region.
Can lifestyle changes or existing medications lower Lp(a) levels?
Lp(a) levels are largely genetically determined and are not significantly influenced by diet or exercise. While some emerging therapies are being developed to specifically lower Lp(a), current management for those with elevated Lp(a) focuses on aggressively controlling all other modifiable cardiovascular risk factors, such as LDL cholesterol, blood pressure, and diabetes, through lifestyle changes and appropriate medications.
Who should consider getting tested for Lp(a)?
Major medical guidelines recommend that all adults consider getting their Lp(a) level measured at least once in their lifetime as part of initial lipid screening. Testing is particularly important for individuals with a family history of high Lp(a) or premature cardiovascular disease, a personal history of ASCVD not explained by other risk factors, or a diagnosis of familial hypercholesterolemia.
